Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
This article was originally published in PharmAsia News
Executive Summary
Emerging markets, the key driver for Reckitt Benckiser's nearly 20 percent net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S